Related Research Articles
Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of English origin, it was produced by the pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Rosiglitazone is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.
Sir Christopher Charles Gent HonFREng is a British businessman, He is the former chief executive officer of Vodafone, a British multinational mobile phone company. Until 2015, he served as the non-exec chairman of GlaxoSmithKline, the world's fourth largest pharmaceutical company. According to the Financial Times 15th August 2022, he was fined £80,000 by the FCA for insider trading.
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.
Smith, Kline & French (SKF) was an American pharmaceutical company.
Sir Andrew Philip Witty is a British business executive, who is the chief executive officer (CEO) of UnitedHealth Group. He was the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.
Canada v GlaxoSmithKline Inc is the first ruling of the Supreme Court of Canada that deals with issues involving transfer pricing and how they are treated under the Income Tax Act of Canada ("ITA").
Christopher v. SmithKline Beecham Corp., 567 U.S. 142 (2012), is a US labor law case of the United States Supreme Court. It held that pharmaceutical sales representatives were not eligible for overtime pay. The court ruled in a majority opinion written by Justice Samuel Alito that sales representatives were classified as "outside salesmen" who are exempt from the Department of Labor's regulations regarding overtime pay.
Hal V. Barron is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018 until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year. Prior to this he served as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Deirdre P. Connelly is a Puerto Rican business professional. Connelly is Chairman of the Board of the European Biotech company Genmab A/S, member of the Boards of Macy’s Inc. and the Lincoln Financial Group. Connelly was past President of North America Pharmaceuticals for GlaxoSmithKline from 2009-2015. Connelly is the first woman to hold that title, and one of only two women on GSK's corporate executive team. She is a member of the global Corporate Executive Team and co-chairs the Portfolio Management Board, along with the Chairman of Research and Development.
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.
Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.
Paul-Peter Tak M.D. PhD FMedSci is an immunologist and academic specialising in the fields of internal medicine, rheumatology and immunology. Tak has been the President & CEO of Candel Therapeutics since September 2020.
The New Frontiers Science Park is a science park in Essex, on a redeveloped research site of GlaxoSmithKline (GSK).
Simon Paul Dingemans is an English former banker and businessman. Until May 2019 he was chief financial officer at GlaxoSmithKline. In July 2019 he was appointed chair of the Financial Reporting Council, and was set to lead its transition into the Audit, Reporting and Governance Authority, but left in May 2020.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
Yvonne Greenstreet is a British biotechnology executive. She is chief operating officer of Alnylam Pharmaceuticals, and from 1 January 2022 Alnylam's CEO. She is one of a small number of Black women leading a drug company.